It was also concluded that disrupting the Ras/Raf/MEK/ERK pathway by blocking Prohibitin-cRaf interaction diminished the viability of pancreatic cancer cells in vitro, and inhibits their migration in vitro and in vivo [26]. This evidence concerns the gene RAF1 and familial pancreatic carcinoma.